Alto Neuroscience

Alto Neuroscience

  • Founded: 2019
  • Location: Los Altos, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: PTSD, depression
  • Drug types: NEU, PSY
  • Lead product: ALTO-100
  • Product link:
  • Funding: $25M B Jan 2023; $35M B Oct 2022; $32M A Oct 2021; $8M seed
  • Investors: Sobrato Capital, Novartis Pharma AG, Valor Equity Partners, Korify Capital, Vine Ventures, Gaingels, Alpha Wave Ventures

job board

Short description:

AI-derived brain biomarkers for therapeutic matching

Drug notes:

ALTO-202 Clin2 PTSD, depression; ALTO-300 Clin1 depression; ALTO-101 Clin1 neurodegenerative & neuropsychiatric conditions; ALTO-203 Clin1 neurodegenerative & neuropsychiatric conditions; combo preograms Clin1 neurodegenerative & neuropsychiatric conditions

Long description:

Alto Neuroscience is creating precision medicines to help patients with mental health disorders. Ten of millions of people in the US suffer from mental health disorders that lack effective treatment. Much of this is due to a lack of consideration of how different people respond to the same drug. Alto has built a pipeline of drugs and tests that identify which patients achieve the best response. The pipeline is built from Alto’s AI-enabled platform that identifies responsive patients and drives drug development using biomarkers. The drug candidates are all clinical-stage which will ensure speed with data collection. Alto’s initial clinical trial studies are focused on depression and PTSD, but they hope to scale their pipeline and biomarker platform to other mental health conditions.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy